Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SpyGlass Pharma, Inc. Common Stock (SGP)
Aliso Viejo, CA, US
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.68% | -11.48% | -15.00% | -28.57% | -19.70% | -19.70% | -19.70% | -19.70% | -19.70% | -19.70% | -19.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
62.00
+212.0%
|
| Last Year | 1 |
62.00
+212.0%
|
| All Time | 1 |
62.00
+212.0%
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.75% | 432.7K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.39% | 822.1K | 0.50% |
| 3 | Affinity World Leaders Equity ETF WLDR | 0.28% | 252.4K | 1.05% |
| 4 | Principal Real Estate Active Opportunities ETF BYRE | 0.24% | 64.9K | 0.60% |
| 5 | iShares Micro-Cap ETF IWC | 0.06% | 836.2K | 0.60% |
| 6 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 351.6K | 0.65% |
| 7 | John Hancock Investments - Multifactor Developed International ETF JHMD | 0.03% | 287.5K | 0.43% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 35.9K | 0.42% |
| 9 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.03% | 69.1K | 0.35% |
| 10 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.02% | 49.1K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick H. Mooney | CEO & Director | 659.6K | male |
| Chetan Pujara | Chief Research & Development Officer | 523.4K | — |
| Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | 424.2K | — |
| Jean-Frederic Viret | Chief Financial Officer | — | — |
| Long Doan | VP & Head of Clinical Operations | — | male |
| James Robert Dennewill Jr. | Chief Operating Officer | — | male |
| Nina Nguyen | Senior Vice President, Regulatory & Quality | — | female |
| Glenn Sussman | Co-founder & Chief Technology Advisor | — | male |
| Paul Yoo | Senior Vice President of Clinical Development | — | male |
| Rachel Gilette | Vice President of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SGP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
